Orchid Pharma Limited
BSE: ORCHIDPHAR
BSE
741.55
-19.25 (-2.53%)
Prev Close
760.8
Open Price
784.9
Volume
24,701
Today Low / High
733 / 784.9
52 WK Low / High
17.15 / 1144.5
Range
704 - 779
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 741.55, reflecting a change of -19.25 (-2.5302%). The expected target range on the BSE is 704 - 779. The stock is showing a downward trend on the BSE. This could indicate a potential risk for investors who are considering buying at this moment.
Orchid Pharma Limited Graph
Orchid Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Orchid Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 741.55, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 741.55 | 748.97 | 674.07 - 823.86 |
| 756.38 | 605.10 - 907.66 | ||
| 763.80 | 534.66 - 992.94 | ||
| Bearish Scenario | 741.55 | 734.13 | 660.72 - 807.55 |
| 726.72 | 581.38 - 872.06 | ||
| 719.30 | 503.51 - 935.09 |
Overview of Orchid Pharma Limited
ISIN
INE191A01027
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
372
Market Cap
0
Last Dividend
0
Official Website
IPO Date
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 921.93 Cr | 567.16 Cr | 354.76 Cr | 0.3848 | 8.37 Cr | 0.00 Cr | 258.16 Cr | 99.66 Cr | 19.65 | 116.99 Cr | 0.1081 |
| 2023-03-31 | 665.90 Cr | 595.21 Cr | 70.69 Cr | 0.1062 | 6.36 Cr | 0.00 Cr | 29.67 Cr | 46.32 Cr | 11.35 | 84.46 Cr | 0.0696 |
| 2022-03-31 | 559.56 Cr | 542.86 Cr | 16.70 Cr | 0.0298 | 6.63 Cr | 0.00 Cr | -32.45 Cr | -1.95 Cr | -0.48 | 54.58 Cr | -0.0035 |
| 2021-03-31 | 450.06 Cr | 468.10 Cr | -18.04 Cr | -0.0401 | 4.81 Cr | 0.00 Cr | -49.70 Cr | -116.53 Cr | -28.55 | 59.21 Cr | -0.2589 |
| 2020-03-31 | 483.80 Cr | 484.83 Cr | -1.03 Cr | -0.0021 | 11.93 Cr | 0.00 Cr | -70.10 Cr | -131.07 Cr | -14.75 | 47.82 Cr | -0.2709 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 21.11 Cr | 1,687.91 Cr | 420.63 Cr | 1,267.2854 Cr | 174.61 Cr | 153.50 Cr | 326.37 Cr | 696.41 Cr | 0.00 Cr | 0.00 Cr | 49.69 Cr | 285.5696 Cr |
| 2023-03-31 | 26.61 Cr | 1,311.31 Cr | 691.22 Cr | 620.0884 Cr | 399.91 Cr | 373.29 Cr | 238.09 Cr | 621.19 Cr | 1.68 Cr | 0.00 Cr | 44.44 Cr | 371.8917 Cr |
| 2022-03-31 | 8.06 Cr | 1,193.40 Cr | 614.58 Cr | 578.8193 Cr | 336.51 Cr | 328.46 Cr | 175.72 Cr | 604.82 Cr | 8.79 Cr | 0.00 Cr | 45.50 Cr | 240.7783 Cr |
| 2021-03-31 | 19.11 Cr | 1,386.59 Cr | 802.24 Cr | 584.3472 Cr | 521.30 Cr | 502.19 Cr | 158.87 Cr | 677.51 Cr | 0.04 Cr | 0.00 Cr | 0.42 Cr | 142.0818 Cr |
| 2020-03-31 | 174.03 Cr | 1,657.40 Cr | 959.98 Cr | 697.4242 Cr | 634.95 Cr | 460.93 Cr | 174.40 Cr | 858.77 Cr | 1.47 Cr | 0.00 Cr | 0.34 Cr | 174.9382 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 19.2151 Cr | -26.9317 Cr | 25.2217 Cr | -130.8937 Cr | 17.5051 Cr | 21.1060 Cr | -150.1088 Cr | 99.6568 Cr | 28.3351 Cr | 0.0000 Cr | -62.1454 Cr |
| 2023-03-31 | -13.4267 Cr | -31.6749 Cr | 63.3921 Cr | -98.3398 Cr | 18.2905 Cr | 18.2905 Cr | -84.9131 Cr | 53.0934 Cr | 0.0000 Cr | 0.0000 Cr | -56.0817 Cr |
| 2022-03-31 | 60.9510 Cr | 112.4481 Cr | -184.7864 Cr | 46.5475 Cr | -11.3873 Cr | -11.3873 Cr | -14.4035 Cr | -60.4214 Cr | 0.0000 Cr | 0.0000 Cr | 2.5369 Cr |
| 2021-03-31 | -15.6520 Cr | 66.5344 Cr | -125.0800 Cr | -16.2560 Cr | -74.1976 Cr | -74.1976 Cr | -0.6040 Cr | -95.2489 Cr | 0.0000 Cr | 0.0000 Cr | -33.4985 Cr |
| 2020-03-31 | 104.6528 Cr | 142.9370 Cr | -250.0092 Cr | 100.4104 Cr | -2.4194 Cr | -2.4194 Cr | -4.2424 Cr | -69.6918 Cr | 0.0000 Cr | 0.0000 Cr | 14.0628 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 172.93 Cr | 98.87 Cr | 74.06 Cr | 0.4283 | 52.45 Cr | 14.91 Cr | 2.94 | 14.16 Cr | 0.0862 |
| 2025-03-31 | 237.48 Cr | 160.96 Cr | 76.52 Cr | 0.3222 | 44.04 Cr | 22.29 Cr | 4.40 | 27.94 Cr | 0.0939 |
| 2023-12-31 | 220.59 Cr | 150.35 Cr | 70.24 Cr | 0.3184 | 26.12 Cr | 29.43 Cr | 5.80 | 35.39 Cr | 0.1334 |
| 2023-09-30 | 198.76 Cr | 147.73 Cr | 51.03 Cr | 0.2567 | 15.47 Cr | 19.80 Cr | 3.90 | 23.31 Cr | 0.0996 |
| 2023-06-30 | 182.92 Cr | 136.00 Cr | 46.92 Cr | 0.2565 | 14.43 Cr | 9.40 Cr | 1.85 | 22.14 Cr | 0.0514 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 179.73 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -1,267.29 Cr |
| 2025-03-31 | 21.11 Cr | 0.02 Cr | 21.12 Cr | 241.83 Cr | 326.37 Cr | 807.42 Cr | 696.41 Cr | 1,687.91 Cr | 420.63 Cr |
| 2023-09-30 | 50.36 Cr | 0.00 Cr | 50.36 Cr | 187.59 Cr | 222.36 Cr | 497.40 Cr | 622.48 Cr | 1,492.08 Cr | 384.24 Cr |
| 2023-03-31 | 26.61 Cr | 4.01 Cr | 30.63 Cr | 215.35 Cr | 238.09 Cr | 501.01 Cr | 621.19 Cr | 1,311.31 Cr | 691.22 Cr |
| 2022-09-30 | 12.69 Cr | 0.00 Cr | 12.69 Cr | 150.13 Cr | 236.02 Cr | 495.72 Cr | 615.68 Cr | 1,165.32 Cr | 543.57 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 14.91 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 22.29 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,763.30 | ₹4,230,747,352,601.00 | ₹1,200,917.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,387.50 | ₹1,695,680,554,750.00 | ₹348,445.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹4,435.00 | ₹1,501,005,526,400.00 | ₹360,000.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,305.00 | ₹1,086,501,487,950.00 | ₹2,296,188.00 |
| Lupin Limited | LUPIN | ₹2,293.00 | ₹1,047,999,599,000.00 | ₹1,104,217.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹918.70 | ₹924,427,166,613.00 | ₹564,622.00 |
| Mankind Pharma Limited | MANKIND | ₹2,165.00 | ₹893,722,980,880.00 | ₹802,350.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,215.20 | ₹705,790,132,270.00 | ₹3,039,195.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,646.00 | ₹675,063,990,000.00 | ₹231,441.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,078.50 | ₹586,554,381,507.00 | ₹455,455.00 |
| Laurus Labs Limited | LAURUSLABS | ₹1,075.00 | ₹580,345,825,650.00 | ₹2,096,375.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,523.30 | ₹386,467,635,279.00 | ₹102,381.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹3,019.50 | ₹377,243,116,668.00 | ₹185,673.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹2,087.90 | ₹335,165,447,241.00 | ₹172,357.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,425.00 | ₹270,140,869,500.00 | ₹90,094.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,387.00 | ₹225,376,638,403.00 | ₹212,895.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,889.00 | ₹222,225,000,000.00 | ₹2,581.00 |
| Eris Lifesciences Limited | ERIS | ₹1,380.40 | ₹188,033,796,336.00 | ₹30,282.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹976.20 | ₹174,847,055,094.00 | ₹5,721,410.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,366.00 | ₹171,484,296,374.00 | ₹27,191.00 |
| Granules India Limited | GRANULES | ₹599.95 | ₹145,589,096,164.00 | ₹775,189.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹736.90 | ₹144,847,366,076.00 | ₹143,344.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹906.00 | ₹143,482,991,688.00 | ₹305,240.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,729.00 | ₹131,424,222,384.00 | ₹21,588.00 |
| Cohance Lifesciences Limited | COHANCE | ₹308.75 | ₹118,117,604,475.00 | ₹467,933.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹912.30 | ₹111,972,052,800.00 | ₹41,727.00 |
| Viyash Scientific Limited | VIYASH | ₹220.00 | ₹95,965,222,980.00 | ₹684,579.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,130.00 | ₹85,154,829,660.00 | ₹7,924.00 |
| Strides Pharma Science Limited | STAR | ₹860.15 | ₹79,282,359,947.00 | ₹85,838.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹479.00 | ₹73,335,885,782.00 | ₹136,599.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹708.95 | ₹64,264,396,246.00 | ₹171,834.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹328.00 | ₹64,150,835,648.00 | ₹194,469.00 |
| FDC Limited | FDC | ₹365.80 | ₹59,555,928,727.00 | ₹46,681.00 |
| Sequent Scientific Limited | SEQUENT | ₹202.40 | ₹50,564,340,966.00 | ₹13,647.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹129.38 | ₹41,986,603,055.00 | ₹619,352.00 |
| Innova Captab Limited | INNOVACAP | ₹668.00 | ₹38,226,252,572.00 | ₹12,206.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹318.90 | ₹34,749,023,009.00 | ₹32,184.00 |
| Suven Life Sciences Limited | SUVEN | ₹150.24 | ₹34,175,693,760.00 | ₹112,596.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹370.50 | ₹33,815,535,000.00 | ₹60,674.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹635.60 | ₹32,237,063,138.00 | ₹129,617.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹1,897.80 | ₹31,387,742,667.00 | ₹9,696.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹279.00 | ₹27,978,819,174.00 | ₹39,130.00 |
Key Executives
No executive data available.
FAQs about Orchid Pharma Limited
What is the current market price of the stock?
The current price is ₹741.55.
What is the 52-week price range?
The range is ₹17.15-1144.5.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 81.43.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Orchid Pharma Limited (ISIN: INE191A01027) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹0.00 crores and an average daily volume of 372 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.